This study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoembolization for stage IV lung squamous cell carcinoma.
Squamous cell carcinoma of the lung confirmed by histology or cytology;
According to the TNM staging system of the 9th edition of American Cancer Association, it was assessed as stage IV.
Has received standard first-line chemotherapy immunotherapy for 4~6 cycles, and achieved partial remission or disease stability according to the efficacy evaluation of RECIST1.1;
The patient is 18-80 years old;
There is epidermal growth factor receptor (EGFR) sensitive mutation or anaplasticlymphomakinase (ALK) gene translocation;
Have a history of allergy to contrast agents or chemotherapy drugs;
Received other anti-tumor treatments other than standard first-line chemotherapy immunotherapy;
Arrhythmia with myocardial ischemia or myocardial infarction above grade II and poor control (including QTc interval ≥450ms for men and ≥ 470 ms for women);